Novel PYY3-36 Analog Treats Obesity, Diabetes, Depression
Summary
The USPTO published patent application US20260109743A1 by inventor Tao Sun disclosing a novel human PYY3-36 analog. The analog demonstrates therapeutic effects across metabolic diseases including obesity, diabetes, and fatty liver, as well as mood disorders such as anxiety and depression. The application was filed on December 16, 2024 under application number 18982094.
“The present disclosure relates to the field of medicine and discloses a novel human PYY3-36 analog.”
About this source
USPTO classification C07K covers peptides: short amino-acid chains that form the backbone of antibodies, hormones, vaccines, and increasingly a wider class of therapeutic modalities. Every newly published application in C07K lands in this feed, around 175 a month. Applications publish 18 months after filing, so this feed reveals what antibody engineering groups, vaccine developers, and plant biotech researchers were working on in the prior year and a half. Watch this if you compete in biologics, file freedom-to-operate analyses on antibody drug candidates, scout acquisition targets in vaccine platforms, or track protein-based agricultural biotech filings.
What changed
The USPTO published patent application US20260109743A1 disclosing a novel human PYY3-36 analog. The analog is designed to treat metabolic diseases including obesity, diabetes, and fatty liver (A61P 3/04, A61P 3/10, A61P 1/16), as well as mood disorders including anxiety and depression (A61P 25/22, A61P 25/24). The application was filed December 16, 2024 under application number 18982094.\n\nPharmaceutical and biotechnology companies developing peptide-based therapeutics for metabolic or neurological indications should monitor this application's prosecution. While a published application does not guarantee grant, the broad therapeutic claims covering both metabolic syndrome and psychiatric conditions indicate potential competition in the gut-brain axis therapeutic space.
Archived snapshot
Apr 23, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
PYY3-36 Analog and Use Thereof in Treating Disease
Application US20260109743A1 Kind: A1 Apr 23, 2026
Inventors
Tao Sun
Abstract
The present disclosure relates to the field of medicine and discloses a novel human PYY3-36 analog. Compared with the naturally-occurring sequence of PYY3-36, the analog has a remarkable effect on ameliorating metabolic diseases such as obesity, diabetes and fatty liver, and on mood disorders such as anxiety and depression.
CPC Classifications
C07K 14/4703 A61P 1/16 A61P 3/04 A61P 3/10 A61P 25/22 A61P 25/24 A61K 38/00
Filing Date
2024-12-16
Application No.
18982094
Mentioned entities
Parties
Related changes
Get daily alerts for USPTO Patent Applications - Peptides (C07K)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Applications - Peptides (C07K) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.